|
What’s New In Hypertension Since The
JNC 7 Guidelines
This activity is an archive of
the live session held at the 2009 Fall Managed Care Forum. If you
participated in the live activity, you are not eligible for
continuing education credits from this archive.
This activity is valid from March 1, 2010 to March 1, 2011 |
|
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This activity is supported by an educational grant from
TAKEDA PHARMACEUTICALS NORTH AMERICA, INC
PLEASE CLICK HERE TO
VIEW PRESENTATION
PLEASE CLICK HERE FOR POST TEST AND
EVALUATION
Instructions for CME/CEU: View the presentation, answer the post test,
complete the evaluation form and submit to keads@namcp.org. A score
of 70% must be achieved on the post test to receive continuing
education credits. You will have the option on the post
test/evaluation page to submit your forms electronically or by
faxing them to Katie Eads at 804-747-5316.
Description
Hypertension continues to be a leading health problem, not only in
sheer numbers of affected individuals but because more than 70% of
people who receive care do not achieve adequate blood pressure
control. How can clinicians do better in helping their patients
achieve better control of hypertension? This session will look at
what the guidelines have to say and opportunities for improved
outcomes.
Goal
The goal of this activity is to provide medical directors from
plans, purchasers and provider systems and nurse case managers with
appropriate education on Hypertension and its impact on managed care
environments. Participants will be able to:
-
Understand the scope
of the hypertension problem, evidence for BP control, goals for
BP control, and improving BP control rates
-
Understand the
reasoning for supporting self-monitored home BP measurement
-
Understand the
barriers toward more effective BP control, including those that
involve the Health Care Provider, Patient, and Payer (Health
Care System), with special emphasis on the role of the provider
and the importance of Clinical Inertia
-
Understand the newer
BP trials since JNC 7 and their clinical implications on the
treatment of hypertension
|
Faculty: |
Jan Basile, MD
Professor of Medicine, Medical University of South
Carolina, Charleston, SC. |
| |
|
|
Disclosure:
|
Grant/Research support: AstraZeneca, Boehringer
Ingelheim, Novartis
Speakers Bureau: Abbott Laboratories, AstraZeneca,
Boehringer Ingelheim, Forest, GSK, Merck, Novartis,
Pfizer, Inc., Daiichi-Sankyo |
|
|
The NAMCP planning
committee has no real or perceived financial
relationships to disclose. |
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to sponsor continuing medical education for physicians.
NAMCP designates this activity for a maximum of 1 AMA PRA Category I
creditsTM. Each physician should claim credit commensurate with the
extent of their participation in the activity.
The American Association of Managed Care Nurses (AAMCN) has been
approved as a provider of continuing education by the Virginia
Nurses Association (VNA). VNA is accredited as an approver of
continuing education in nursing by the American Nurses Credentialing
Center’s Commission on Accreditation. Nurses who complete this
activity will be awarded 1.0 contact hours.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is
supported by an educational grant from
TAKEDA PHARMACEUTICALS
NORTH AMERICA, INC
|